Rankings
▼
Calendar
KROS Q3 2019 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
KROS
Keros Therapeutics, Inc.
$424M
Q3 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
Gross Profit
$0
0.0% margin
Operating Income
-$2M
-93.0% margin
Net Income
-$4M
-142.0% margin
EPS (Diluted)
$-0.45
QoQ Revenue Growth
+0.0%
Cash Flow
Operating Cash Flow
-$3M
Free Cash Flow
-$3M
Stock-Based Comp.
$17,000
← FY 2019
All Quarters
Q4 2019 →